Delivery Order SPE2DB22D2007-SPE2DB23FJ6GM
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $22,982.83 delivery order covers the supply of Biktarvy 50-200-25 30S, a prescription medication, to support military healthcare programs. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $18,218.68 firm-fixed-price delivery order is for the pharmaceutical product Biktarvy 50-200-25 mg Tablet, with an ultimate completion date of November 7, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- This federal contract award is for the delivery of pharmaceutical products and medical supplies to the U.S. government. The prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a Delivery Order (SPE2DX22FCEK5) valued at $92,495.09 by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense (DoD). The contract covers the delivery of Biktarvy 50-200-25 mg tablets to support military and veterans' healthcare programs....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $42,397.67 delivery order contract is for the supply of Biktarvy 50-200-25 mg tablets. The contract has a firm fixed price pricing type and an ultimate completion date of May 25, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,295.65, is a Delivery Order for the provision of the drug Biktarvy, a 50-200-25 mg tablet. The contract has no set-aside designation, indicating full and open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also does business as...
- This federal contract award, valued at $134,215.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a prescription medication, to support the Department of Defense (DoD) and its healthcare programs. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December...
- This federal contract award, valued at $82,322.33, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of Biktarvy 50-200-25 mg tablets, a specialty medication, to support military and government healthcare programs. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order valued at $7,525.83 for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of May 1, 2024 and is a Firm Fixed Price arrangement. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablet, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The $51,915.00 delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a firm fixed price, delivery order type, without any set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $102,220.74 delivery order contract is for the supply of pharmaceutical products, including the HIV medication Biktarvy 50-200-25 mg tablets. The contract has a period of performance ending on January 24, 2024 and utilizes a firm fixed price pricing structure. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB23FJ6GMDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $42,695.01, is a delivery order for the pharmaceutical product Biktarvy 50-200-25 mg tablet. The contract has no set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. In addition, Amerisourcebergen holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs demonstrate Amerisourcebergen's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.7k | 9/20/23 |